Thayse R. Brüggemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thayse R. Brüggemann has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Bruce David Levy
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
4 shared publications - Melody G. Duvall
Harvard Medical School
3 shared publications - Julie Nijmeh
Pulmonary and Critical Care Medicine Division, Department of Medicine Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA
2 shared publications Benjamin M. Gaston
Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH 44106, USA
1 shared publicationBruce Levy
Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital, USA
1 shared publication- Charles Nicholas Serhan
Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School
1 shared publication
Latest Publications
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (5) , L624-L633
A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness
This is the first report of an Anticalin protein engineered to neutralize IL-23 (AcIL-23). Airway administration of AcIL-23 in mice regulated allergen-driven airway inflammation, mucous cell metaplasia, and methacholine-induced airway hyperresponsiveness. In mixed granulocytic allergic lung inflammation, immune regulation of IL-23 was broader than neutralization of either IL-17 or IL-5.
- 1 November 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (5) , L624-L633
A new Anticalin protein for IL-23 inhibits non-type 2 allergen-driven mouse lung inflammation and airway hyperresponsiveness
This is the first report of an Anticalin protein engineered to neutralize IL-23 (AcIL-23). Airway administration of AcIL-23 in mice regulated allergen-driven airway inflammation, mucous cell metaplasia, and methacholine-induced airway hyperresponsiveness. In mixed granulocytic allergic lung inflammation, immune regulation of IL-23 was broader than neutralization of either IL-17 or IL-5.
- 11 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23807
15‐epi‐lipoxin A 5 promotes neutrophil exit from exudates for clearance by splenic macrophages
Specialized proresolving mediators (SPMs) promote local macrophage efferocytosis but excess leukocytes early in inflammation require additional leukocyte clearance mechanism for resolution. Here, neutrophil clearance mechanisms from localized acute inflammation were investigated in mouse dorsal air pouches. 15‐HEPE (15‐hydroxy‐5 Z ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid) levels were increased in the exudates. Activated human neutrophils converted 15‐HEPE to lipoxin A 5 (5 S ,6 R ,15 S ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), 15‐epi‐lipoxin A 5 (5 S ,6 R ,15 R ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), and resolvin E4 (RvE4; 5 S ,15 S ‐dihydroxy‐6 E ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid). Exogenous 15‐epi‐lipoxin A 5 , 15‐epi‐lipoxin A 4 and a structural lipoxin mimetic significantly decreased exudate neutrophils and increased local tissue macrophage efferocytosis, with comparison to naproxen. 15‐epi‐lipoxin A 5 also cleared exudate neutrophils faster than the apparent local capacity for stimulated macrophage efferocytosis, so the fate of exudate neutrophils was tracked with CD45.1 variant neutrophils. 15‐epi‐lipoxin A 5 augmented the exit of adoptively transferred neutrophils from the pouch exudate to the spleen, and significantly increased splenic SIRPa + and MARCO + macrophage efferocytosis. Together, these findings demonstrate new systemic resolution mechanisms for 15‐epi‐lipoxin A 5 and RvE4 in localized tissue inflammation, which distally engage the spleen to activate macrophage efferocytosis for the clearance of tissue exudate neutrophils.
- 11 July 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (14) , e23807
15‐epi‐lipoxin A 5 promotes neutrophil exit from exudates for clearance by splenic macrophages
Specialized proresolving mediators (SPMs) promote local macrophage efferocytosis but excess leukocytes early in inflammation require additional leukocyte clearance mechanism for resolution. Here, neutrophil clearance mechanisms from localized acute inflammation were investigated in mouse dorsal air pouches. 15‐HEPE (15‐hydroxy‐5 Z ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid) levels were increased in the exudates. Activated human neutrophils converted 15‐HEPE to lipoxin A 5 (5 S ,6 R ,15 S ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), 15‐epi‐lipoxin A 5 (5 S ,6 R ,15 R ‐trihydroxy‐7 E ,9 E ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid), and resolvin E4 (RvE4; 5 S ,15 S ‐dihydroxy‐6 E ,8 Z ,11 Z ,13 E ,17 Z ‐eicosapentaenoic acid). Exogenous 15‐epi‐lipoxin A 5 , 15‐epi‐lipoxin A 4 and a structural lipoxin mimetic significantly decreased exudate neutrophils and increased local tissue macrophage efferocytosis, with comparison to naproxen. 15‐epi‐lipoxin A 5 also cleared exudate neutrophils faster than the apparent local capacity for stimulated macrophage efferocytosis, so the fate of exudate neutrophils was tracked with CD45.1 variant neutrophils. 15‐epi‐lipoxin A 5 augmented the exit of adoptively transferred neutrophils from the pouch exudate to the spleen, and significantly increased splenic SIRPa + and MARCO + macrophage efferocytosis. Together, these findings demonstrate new systemic resolution mechanisms for 15‐epi‐lipoxin A 5 and RvE4 in localized tissue inflammation, which distally engage the spleen to activate macrophage efferocytosis for the clearance of tissue exudate neutrophils.
- Open Access
- 3 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
The Maresin 1–LGR6 axis decreases respiratory syncytial virus-induced lung inflammation
The resolution of infection is an active process with specific molecular and cellular mechanisms that temper inflammation and enhance pathogen clearance. Here, the specialized pro-resolving mediator (SPM) Maresin 1 (MaR1) inhibited respiratory syncytial virus (RSV)-induced inflammation. inlerleukin-13 production from type 2 innate lymphoid cells (ILC) and CD4 T helper type 2 cells was decreased by exogenous MaR1. In addition, MaR1 increased amphiregulin production and decreased RSV viral transcripts to promote resolution. MaR1 also promoted interferon-β production in mouse lung tissues and also in pediatric lung slices. MaR1 significantly inhibited the RSV-triggered aberrant inflammatory phenotype in FoxP3-expressing Tregs. The receptor for MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was constitutively expressed on Tregs. Following RSV infection, mice lacking Lgr6 had exacerbated type 2 immune responses with an increased viral burden and blunted responses to MaR1. Together, these findings have uncovered a multi-pronged protective signaling axis for MaR1–Lgr6, improving Tregs’s suppressive function and upregulating host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimately promoting restoration of airway mucosal homeostasis.
- 3 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
Open AccessThe Maresin 1–LGR6 axis decreases respiratory syncytial virus-induced lung inflammation
The resolution of infection is an active process with specific molecular and cellular mechanisms that temper inflammation and enhance pathogen clearance. Here, the specialized pro-resolving mediator (SPM) Maresin 1 (MaR1) inhibited respiratory syncytial virus (RSV)-induced inflammation. inlerleukin-13 production from type 2 innate lymphoid cells (ILC) and CD4 T helper type 2 cells was decreased by exogenous MaR1. In addition, MaR1 increased amphiregulin production and decreased RSV viral transcripts to promote resolution. MaR1 also promoted interferon-β production in mouse lung tissues and also in pediatric lung slices. MaR1 significantly inhibited the RSV-triggered aberrant inflammatory phenotype in FoxP3-expressing Tregs. The receptor for MaR1, leucine-rich repeat-containing G protein-coupled receptor 6 (LGR6), was constitutively expressed on Tregs. Following RSV infection, mice lacking Lgr6 had exacerbated type 2 immune responses with an increased viral burden and blunted responses to MaR1. Together, these findings have uncovered a multi-pronged protective signaling axis for MaR1–Lgr6, improving Tregs’s suppressive function and upregulating host antiviral genes resulting in decreased viral burden and pathogen-mediated inflammation, ultimately promoting restoration of airway mucosal homeostasis.
- Top Cited Papers
- 3 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (26)
Neutrophil cytoplasts induce T H 17 differentiation and skew inflammation toward neutrophilia in severe asthma
Neutrophil cytoplasts promote T H 17 inflammation.
- 3 August 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (26)
Top Cited PapersNeutrophil cytoplasts induce T H 17 differentiation and skew inflammation toward neutrophilia in severe asthma
Neutrophil cytoplasts promote T H 17 inflammation.
- 6 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense.
Leukocyte trafficking mechanisms in response to inflammatory stimuli are critical to health and host defense. This article has identified an interesting new mechanism for innate lymphoid cell trafficking to a target organ. ILC2s were thought to be mostly tissue resident cells; however, this article shows that in response to epithelial derived cytokines such as IL-25 and IL-33, subpopulations of ILC2s are recruited to infected lungs. Lin-, ST2-, KLRG1hi inflammatory ILC2s (iILC2) are recruited from the intestine to the lungs in a sphingosine-1-phosphate-dependent manner in response to IL-25, whereas Lin-, ST2+, KLRG1int tissue naturally resident ILC2s (nILC2) are more responsive to IL-33. These important new findings increase our understanding of innate immune responses to infection and regulatory mechanisms to enhance host defense in the lungs.
- 6 March 2018
- Published by H1 Connect
Faculty Opinions recommendation of S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense.
Leukocyte trafficking mechanisms in response to inflammatory stimuli are critical to health and host defense. This article has identified an interesting new mechanism for innate lymphoid cell trafficking to a target organ. ILC2s were thought to be mostly tissue resident cells; however, this article shows that in response to epithelial derived cytokines such as IL-25 and IL-33, subpopulations of ILC2s are recruited to infected lungs. Lin-, ST2-, KLRG1hi inflammatory ILC2s (iILC2) are recruited from the intestine to the lungs in a sphingosine-1-phosphate-dependent manner in response to IL-25, whereas Lin-, ST2+, KLRG1int tissue naturally resident ILC2s (nILC2) are more responsive to IL-33. These important new findings increase our understanding of innate immune responses to infection and regulatory mechanisms to enhance host defense in the lungs.